mgm2020 • 13 hours ago Flag
7users liked this postsusers disliked this posts2Reply
Has everyone watched the Cramer video regarding speculative developmental bios???
WATCH IT!! He says that NOW is the time to buy speculative developmental-stage biotechs with good pipelines and "shots on goal" because "economic chaos does not apply to unmet medical needs." He also says that the smaller companies tend to be acquisition targets of big pharma whose pipelines and IP are becoming exhausted. And---he says that these companies tend to trade higher leading into approvals. He spotlighted 3 companies. Receptos and Alder are 2 of them. NEITHER have an approved product yet---they are ALL either in trials or have preclinical data. Alder has gone from $10 to $50 in 12 months and only has 2 drug candidates in trials as well as additional preclinical data supporting other candidates. Receptos has gone from $13 to $200 in 24 months with NO APPROVED DRUGS and they are advancing candidates in autoimmune, anti-inflammatory-----and Crohn's disease and ulcerative colitis---SOUND FAMILIAR?? He says that JUST their drugs for those 2 conditions could be worth $2 BILLION. Currently Receptos has a market cap of $5.5 BILLION with NO approved drug and only 1 compound in phase 3---for MS. And Receptos LOST $1.29/share last quarter!!! But these are the types of developmental biotechs that investors are willing to pay for----and the stocks that earn the high valuations. IDRA WILL BECOME one of these companies. It has the science, it has the leadership, it has the PIPELINE, it has a more advanced GSO than ISIS, they are going after orphan diseases AND unmet medical need, and it has the TIME! I am sure that most shareholders that were in Receptos 24 months ago at $13 would have been ridiculed if they would have predicted a $200 stock price in 24 months! Same with Alder going from $10 to $50 in 12 months---but it DID happen.
Just the fact that it has taken Parsons this long to formulate a remedy , along with his first misjudgment(SC struck him down), shows that Parsons judgment is nothing but speculation.
Looks like the investment community including the PIP shareholders, just like SIGA management, believes 194m is too much to pay for this dispute. I say this based on 1) SIGA has the money and PIP would get it one way or another unless the SC changes the award. That seems pretty cut and dried. So why doesn't PIP longs buy up all PIP stock which should be at least double from here? 2) You don't see PIP insiders buying PIP stock. ( Chang the CFO is selling) 3) You don't see institutions buying. 4) SIGA has much more insider and institution holding than PIP.
Now answer me, why isn't PIP's PPS rocketing up? HUMMMMMMM????
I guess Parson is a "practicing" judge being "well, if that pill didn't work, then try this one that I have already rejected being there was nothing in the capsule."
wants to negotiate with SIGA. I think the SC has told Parsons not to sent up such nonsense to them. Remember PIP has the upper hand. So why would they now want to negotiate?
I think the SC does not believe and I totally agree, that SIGA should suffer more than they would have if an agreement was consummated. Yet, even with that I do not see that the courts should be able to force an agreement, unless there was a signed contract. Negotiation in bad faith, what price? Someone is crazy and his last name is Parson.
A worsening outbreak of dengue fever in Japan has claimed its first celebrities -- two young models sent on assignment to the Tokyo park believed to be its source.
Yes, if there had been a signed contract, then SIGA should have to pay Parsons judgment. But there wasn't!
In other words if he had gotten it right the first time, you would not be posting on this board now, looking less than me, a moron. Does it hurt?
alibi, did he or did he not fail to get it right? If I am a moron and as I said he failed to get it right, then what does that make you?
JB* A supposedly Open-Market acquisition, but one that was done outside (usually lower) the price range traded that day. The transaction could also represent more shares than the exchange reports as having traded all day. In other words, it could not have been an open-market transaction. Yet it is still potentially significant. Private placements and other corporate actions my explain the non-open market nature of the trade. Including them in your analysis is suggested.